A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12-35 Months.

Trial Profile

A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12-35 Months.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 29 Jan 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 14 Dec 2010 Additional location (South Korea) identified as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top